Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
0.64
-0.03 (-4.26%)
At close: Jun 13, 2025, 3:59 PM
0.66
2.87%
After-hours: Jun 13, 2025, 05:57 PM EDT
-4.26% (1D)
| Bid | 0.64 |
| Market Cap | 9.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.23M |
| EPS (ttm) | -4.99 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -0.4 |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 303,294 |
| Avg. Volume (20D) | 610,650 |
| Open | 0.65 |
| Previous Close | 0.67 |
| Day's Range | 0.63 - 0.67 |
| 52-Week Range | 0.40 - 4.90 |
| Beta | 1.56 |
About MBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-19.83%
Moleculin Biotech shares are trading lower. The co...
Unlock content with
Pro Subscription
4 months ago
+202.38%
Moleculin Biotech shares are trading higher after receiving FDA feedback allowing a reduction in the size of its Phase 3 pivotal trial for Annamycin with Cytarabine.
